Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1626
This examiner grants 74% of resolved cases
Brian E. McDowell serves in Tech Center 1600 and Art Unit 1624, having overseen 1135 resolved cases. His allowance rate stands at 74.1 percent, reflecting a generally favorable environment for patent applicants. The median days to allowance is 816, which indicates a specific timeline for reaching a final disposition in this art unit.
The impact of interviews is particularly notable for this examiner. McDowell demonstrates an interview lift of 30.7 percent, which is an increase over his baseline allowance rate of 74.1 percent. This suggests that personal engagement and technical discussions are effective tools for overcoming rejections. With 1135 resolved cases in his history, the data provides a foundation for practitioners to prioritize interviews as a tactic to improve the likelihood of success and potentially manage the 816-day median pendency. These metrics suggest that applicants in Art Unit 1624 can expect both a high probability of success and a timely resolution.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17277829 | STEROL ANALOGS AND USES THEREOF | Non-Final OA | ModernaTX, Inc. |
| 18639608 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18253726 | COMPOUNDS AS PU. 1 INHIBITORS | Final Rejection | Peking University |
| 18221513 | MODIFIED FLUOROQUINOLONES AND USES THEREOF | Non-Final OA | Technion Research & Development Foundation Limited |
| 18661871 | ELECTRO-PHOTOCHEMICAL SYNTHESIS OF 1,2,4-TRIAZOLO-[4,3-A]PYRAZINE | Non-Final OA | Purdue Research Foundation |
| 17552413 | CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION | Non-Final OA | Purdue Research Foundation |
| 18772655 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | Non-Final OA | Pfizer Inc |
| 18268959 | SOLID FORMS OF A CDK2 INHIBITOR | Final Rejection | PFIZER INC. |
| 18468885 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Final Rejection | Boehringer Ingelheim International GmbH |
| 18117966 | NOVEL HETEROCYCLIC COMPOUNDS | Final Rejection | Hoffmann-La Roche Inc. |
| 18579671 | TWO DIMENSIONAL BENZO[4,5]IMIDAZO[2,1-A]ISOINDOLEINCORPORATED NON-FULLERENE ELECTRON ACCEPTORS FOR ORGANIC PHOTOVOLTAIC DEVICES | Non-Final OA | National Research Council of Canada |
| 17296665 | HALOGENATED ZINC PHTHALOCYANINE PIGMENT AND PRODUCTION METHOD THEREFOR | Non-Final OA | DIC Corporation |
| 18587187 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Non-Final OA | Crinetics Pharmaceuticals, Inc. |
| 17016158 | METHOD AND COMPOSITION FOR ADMINISTERING PROSTAGLANDINS | Non-Final OA | MannKind Corporation |
| 18584163 | METHODS OF PREPARING INTERMEDIATES OF HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Non-Final OA | Corcept Therapeutics Incorporated |
| 18583347 | CRBN LIGANDS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
| 18577856 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | Final Rejection | VICORE PHARMA AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy